Please assess the completion status of the following clinical trial:

Trial Title: Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~MULTIPLE MYELOMA CRITERIA:~Criteria for Cohort A (recently diagnosed subjects; to receive autologous hematopoietic cell transplantation (AHCT)):~* Must have presence of clonal plasma cells in the bone marrow greater or equal to 10% or biopsy proven plasmacytoma~* Must have either:~  1. presence of an M-component (Immunoglobulin G (IgG) or Immunoglobulin G (IgA)) in serum greater or equal to 1g/dl or in urine greater or equal to 200 mg/24 h; or~ 2. presence of an abnormal serum free light chain (FLC) ratio on the serum FLC assay.~Criteria for Cohort B (multiply relapsed multiple myeloma):~* Must have measurable multiple myeloma (MM), as defined by: serum M-protein greater than or equal to 1 g/dL, urine M-protein greater than or equal to 200 mg/24 hours, involved serum free light chain (FLC) level greater than or equal to 10 mg/dL, biopsy proven plasmacytoma, or more than 30% bone marrow plasma cells.~* Must have received at least 2 different treatment regimens for MM.~Other eligibility criteria (applies to both Cohort A and Cohort B, unless specified):~* Age greater than or equal to 18 years and less than or equal to 75 years. In subjects between 65 and 75 years of age, physiologic age and co-morbidity will be thoroughly evaluated before enrolling. Specifically, any history of cardio-vascular pathology or symptoms, not clearly fitting the exclusion criteria will prompt an evaluation by a Clinical Center Cardiologist and eligibility will be considered on a case-by-case basis.~* For Cohort A only, high-dose chemotherapy and AHCT must be planned; with amendment K, post-transplant maintenance therapy will not be permitted.~* Karnofsky performance status (KPS) of 70% or greater. Lower KPS down to 50% may be acceptable if the restriction of activity is solely due to intractable pain from myeloma lesions.~* Ejection fraction (EF) by multi-gated acquisition scan (MUGA) or two-dimensional (2-D) echocardiogram within institution normal limits. In case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more.~* Serum creatinine less than or equal to 2.5 mg/dl,~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 times the upper limit of normal.~* Bilirubin less than or equal to1.5 (except if due to Gilbert's disease).~* Corrected carbon monoxide diffusing capacity (DLCO) greater than or equal to 50% on Pulmonary Function Tests~* No history of abnormal bleeding tendency or predisposition to repeated infections.~* Patients must be able to give informed consent~EXCLUSION CRITERIA:~* Prior allogeneic stem cell transplantation~* Hypertension not adequately controlled by 3 or less medications.~* History of cerebro-vascular accident within 6 months of enrollment.~* History of documented pulmonary embolus within 6 months of enrollment.~* Clinically significant cardiac pathology: myocardial infarction within 6 months prior to enrollment, Class III or IV heart failure according to New York Heart Association (NYHA), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~* Patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis.~* Human immunodeficiency virus (HIV) seropositive~* Patients known or found to be pregnant or who is unwilling to stop breast-feeding.~* Patients of childbearing age who are unwilling to practice contraception or other means of avoiding pregnancy.~Patients may be excluded at the discretion of the principal investigator (PI) if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort B - Relapsed Multiple Myeloma (Type: EXPERIMENTAL): Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma
- Cohort A - Prevention of Relapse (Type: EXPERIMENTAL): Th1/Tc1.Rapa Prevention of Relapse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues